FDA Must Revisit Xifaxan Generic Exclusivity, DC Circ. Says
The D.C. Circuit on Tuesday ordered the U.S. Food and Drug Administration to take another look at Norwich Pharmaceuticals' bid to bring a generic version of a prescription drug for irritable...To view the full article, register now.
Already a subscriber? Click here to view full article